Hyperimmune globulin

CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine

Retrieved on: 
Friday, April 2, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Clinical trials, Other Health, Medicine, Clinical medicine, Branches of biology, Emergent BioSolutions, Hyperimmune globulin, Behring, Grifols, Hyperimmune, Severe acute respiratory syndrome, the ITAC Trial, the CoVIg-19 Plasma Alliance

Analyses remain ongoing and NIAID and the INSIGHT Network intend to publish the full results of the trial soon.

Key Points: 
  • Analyses remain ongoing and NIAID and the INSIGHT Network intend to publish the full results of the trial soon.
  • Since we embarked on this development program, and throughout the pandemic, we have learned much from our scientific research.
  • Four companies provided investigational H-Ig materials for the trial, including CSL Behring and Takeda on behalf of the CoVIg-19 Plasma Alliance, as well as Emergent BioSolutions and Grifols.
  • The Alliance brought together world-leading plasma companies to work on the development of an investigational unbranded polyclonal anti-SARS-CoV-2 hyperimmune globulin medicine intended for the treatment of patients at risk for serious complications from COVID-19.

Rallybio Announces First-in-Human Dosing in RLYB211 Phase 1/2 Study

Retrieved on: 
Tuesday, November 10, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Blood, Transfusion medicine, Antibodies, Human platelet antigen, Platelet, Hyperimmune globulin, Hyperimmune, FNAIT, RLYB211, Rallybio

Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that dosing has commenced in a Phase 1/2 study evaluating RLYB211, a plasma-derived hyperimmune globulin, in healthy male participants.

Key Points: 
  • Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that dosing has commenced in a Phase 1/2 study evaluating RLYB211, a plasma-derived hyperimmune globulin, in healthy male participants.
  • The Phase 1/2 study is a single-blind, placebo-controlled proof-of-concept study designed to establish the dose of RLYB211 that will rapidly clear HPA-1a positive platelets transfused to HPA-1a negative healthy male participants.
  • The study consists of three cohorts, each investigating a different dose of RLYB211.
  • Additional information on the RLYB211 Phase 1/2 study is available at clinicaltrialsregister.eu with EudraCT Number 2019-003459-12.

Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19

Retrieved on: 
Thursday, October 8, 2020
Health, Medicine, Clinical medicine, Antibodies, Antivirals, Glycoproteins, Hyperimmune globulin, Clinical research, Pharmaceutical industry, Remdesivir, Hyperimmune, Coronavirus disease

We are drawing from decades of experience developing treatments on our well-established hyperimmune platform to address this serious public health threat.

Key Points: 
  • We are drawing from decades of experience developing treatments on our well-established hyperimmune platform to address this serious public health threat.
  • Emergent is one of four companies providing hyperimmune globulin products for the trial, which plans to enroll approximately 500 patients across U.S. and international clinical trial sites.
  • The main goal of the trial is to compare the health status of participants treated with hyperimmune globulin plus remdesivir with participants treated with a placebo plus remdesivir.
  • Using its established hyperimmune platforms, Emergent is developing two investigational plasma-based treatments - COVID-19 Human Immune Globulin (COVID-HIG) and COVID-Equine Immune Globulin (COVID-EIG).

Plasma Fractionation Market Worth $41.4 billion by 2027- Exclusive Report Covering Pre and Post COVID-19 Market Analysis by Meticulous Research®

Retrieved on: 
Thursday, September 10, 2020
Branches of biology, Anatomy, Blood, Body fluids, Medical technology, Transfusion medicine, Blood plasma, Hyperimmune globulin, Hyperimmune, Fractionation, Plasma

Limited data is available to suggest that convalescent plasma and hyperimmune globulin may have benefits in the COVID-19 illness.

Key Points: 
  • Limited data is available to suggest that convalescent plasma and hyperimmune globulin may have benefits in the COVID-19 illness.
  • Based on the end user, hospitals and clinics segment is estimated to command the largest share of the overall plasma fractionation market in 2020.
  • Quick Buy Plasma Fractionation Market Research Report: https://www.meticulousresearch.com/buy_now.php?pformat=421&vformat=1249
    Geographically, North America estimated to dominate the global plasma fractionation market in 2020, followed by Europe and Asia-Pacific.
  • The plasma fractionation market has witnessed a number of new product launches; partnership, agreements, & collaborations; expansions; and acquisitions.

Plasma Fractionation Market Worth $41.4 billion by 2027- Exclusive Report Covering Pre and Post COVID-19 Market Analysis by Meticulous Research®

Retrieved on: 
Thursday, September 10, 2020
Branches of biology, Anatomy, Blood, Body fluids, Medical technology, Transfusion medicine, Blood plasma, Hyperimmune globulin, Hyperimmune, Fractionation, Plasma

Limited data is available to suggest that convalescent plasma and hyperimmune globulin may have benefits in the COVID-19 illness.

Key Points: 
  • Limited data is available to suggest that convalescent plasma and hyperimmune globulin may have benefits in the COVID-19 illness.
  • Based on the end user, hospitals and clinics segment is estimated to command the largest share of the overall plasma fractionation market in 2020.
  • Quick Buy Plasma Fractionation Market Research Report: https://www.meticulousresearch.com/buy_now.php?pformat=421&vformat=1249
    Geographically, North America estimated to dominate the global plasma fractionation market in 2020, followed by Europe and Asia-Pacific.
  • The plasma fractionation market has witnessed a number of new product launches; partnership, agreements, & collaborations; expansions; and acquisitions.

The Global Plasma Protein Therapeutics Market is expected to grow from USD 19,578.09 Million in 2018 to USD 37,938.12 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 9.91%

Retrieved on: 
Tuesday, June 2, 2020
Branches of biology, Anatomy, RTT, Blood proteins, Complement deficiency, Blood, Angioedema, C1-inhibitor, Coagulation, Globulin, Blood plasma, Hyperimmune globulin

On the basis of Product, the Global Plasma Protein Therapeutics Market is studied across Albumins, C1-esterase Inhibitors, Coagulation Factors, Hyperimmune Globulins, and Immunoglobulins.

Key Points: 
  • On the basis of Product, the Global Plasma Protein Therapeutics Market is studied across Albumins, C1-esterase Inhibitors, Coagulation Factors, Hyperimmune Globulins, and Immunoglobulins.
  • On the basis of Application, the Global Plasma Protein Therapeutics Market is studied across Hereditary Angioedema, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiency Disorder, and Secondary Immunodeficiency.
  • What are the factors that affect the growth in the Global Plasma Protein Therapeutics Market over the forecast period?
  • Which are the best product areas to be invested in over the forecast period in the Global Plasma Protein Therapeutics Market?

Plasma Donations From Recovered COVID-19 Patients Needed For New Investigational Medication

Retrieved on: 
Thursday, May 7, 2020
Branches of biology, Medicine, Medical specialties, Transfusion medicine, Glycoproteins, Antibodies, Blood, Hyperimmune globulin, Hyperimmune, Blood plasma

Individuals who have recovered from COVID-19 and want to donate plasma now have two options to help sick patients receive immune-boosting antibodies.

Key Points: 
  • Individuals who have recovered from COVID-19 and want to donate plasma now have two options to help sick patients receive immune-boosting antibodies.
  • In addition to convalescent plasma, the latest option is in support of a new investigational medication, known as hyperimmune globulin (H-Ig).
  • Through an unprecedented partnership of world-leading plasma companies, the CoVIg-19 Plasma Alliance was formed to develop this non-branded plasma-derived therapy.
  • Donated plasma from recovered COVID-19 patients contains antibodies that could help the immune system fight the new coronavirus.

Global $28.5Bn Blood Plasma Products Market by 2023 - Major Players are CSL Behring, Shire, Grifols, Octapharma, ADMA Biologics, and Kedrion Biopharma - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 11, 2019
Health, General Health, Branches of biology, Anatomy, Coagulation system, Blood products, Blood, RTT, Transfusion medicine, Hyperimmune globulin, Blood plasma, Prothrombin complex concentrate, Coagulation, Hyperimmune

The "Global Blood Plasma Products Market (2018-2023)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Blood Plasma Products Market (2018-2023)" report has been added to ResearchAndMarkets.com's offering.
  • The global blood plasma products market is forecasted to grow at a CAGR of 6.8% and will reach USD 28.5 Bn in 2023 from USD 20.5 Bn in 2018.
  • The blood plasma products market is segmented based on product types like immunoglobulin, albumin, hyperimmune globulin, coagulation factor VIII, coagulation factor IX, and other plasma products.
  • North America is leading the blood plasma products market and occupied approximately 44.2% of the market in 2018.

Global Markets for Blood Plasma Products, 2017-2018 & Forecast to 2023 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 24, 2019
Health, Physical therapy, Branches of biology, Medicine, Anatomy, Blood, Hematology, Transfusion medicine, Fractionation, Hyperimmune globulin, Blood plasma, Plasma, Hyperimmune, Canadian Plasma Resources

This research report presents an in-depth analysis of the global blood plasma market by product type, application, end user, and geographic market.

Key Points: 
  • This research report presents an in-depth analysis of the global blood plasma market by product type, application, end user, and geographic market.
  • The report also features an in-depth analysis of key companies operating in the global blood plasma market and patents that highlight past, current and projected global technology trends.
  • The blood plasma market is primarily segmented into five major blood plasma components: immunoglobulin, albumin, hyperimmune globulin, coagulation factor concentrates, and other plasma fractionation products.
  • The global blood plasma market is further segmented by application, which helps in understanding the potency of blood plasma products in several therapeutic treatments.

GLOBAL PLASMA FRACTIONATION MARKET 2018-2028

Retrieved on: 
Monday, June 11, 2018
Medicine, Clinical medicine, Anatomy, Blood, Medical signs, RTT, Immune system, Blood plasma fractionation, Coagulation, Globulin, Thrombocytopenic purpura, Hyperimmune globulin

NEW YORK, June 11, 2018 /PRNewswire/ -- Immunoglobulins, Albumins, Clotting Factors, Hyperimmune Globulins, Alpha 1 Antitrypsin Inhibitors (A1PI), C1 Esterase Inhibitors, Primary Immune Deficiency (PID), Secondary Immune Deficiency (SID), Idiopathic Thrombocytopenic Purpura (ITP), Cardiac & Surgery, Emergency Medicine, Haemophilia

Key Points: 
  • NEW YORK, June 11, 2018 /PRNewswire/ -- Immunoglobulins, Albumins, Clotting Factors, Hyperimmune Globulins, Alpha 1 Antitrypsin Inhibitors (A1PI), C1 Esterase Inhibitors, Primary Immune Deficiency (PID), Secondary Immune Deficiency (SID), Idiopathic Thrombocytopenic Purpura (ITP), Cardiac & Surgery, Emergency Medicine, Haemophilia
    In 2017, the global plasma fractionation market was valued at $24bn and is expected to grow at a CAGR of 9.0% in the first half of the forecast period.
  • In 2017, the immunoglobulins submarket held 44.0% of the global plasma fractionation market.
  • The 172-page report provides clear detailed insight into the global plasma fractionation market.
  • - This report also breaks down the revenue forecast for the global plasma fractionation market by type of product: